Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Cr&eacut...
Guardado en:
Autores principales: | Pujals A, Favre L, Gaulard P, Wiels J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd36db5f774b4124b36b99645b5e827a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
por: Provencio M., et al.
Publicado: (2011) -
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
por: Flowers CR, et al.
Publicado: (2012) -
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
por: Farina F, et al.
Publicado: (2014) -
Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
por: John R. Krause, et al.
Publicado: (2021) -
Advances in the diagnosis and management of lymphoma
por: Matasar MJ, et al.
Publicado: (2012)